Analysis | Samples | Factors | Units |
---|---|---|---|
Precellys homogenization (IC-FTMS1) | 15_UK21 | Treatment:13C6Glc_100ug/ml b-glucan | Tissue type:nontumor | normalized corrected peak area |
Precellys homogenization (IC-FTMS1) | 07_UK21 | Treatment:13C6Glc_100ug/ml b-glucan | Tissue type:tumor | normalized corrected peak area |
Precellys homogenization (IC-FTMS1) | 13_UK21 | Treatment:13C6Glc | Tissue type:nontumor | normalized corrected peak area |
Precellys homogenization (IC-FTMS1) | 05_UK21 | Treatment:13C6Glc | Tissue type:tumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 33_UK49 | Treatment:13C6Glc_100ug/ml b-glucan | Tissue type:nontumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 34_UK49 | Treatment:13C6Glc_100ug/ml b-glucan | Tissue type:nontumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 03_UK49 | Treatment:13C6Glc_100ug/ml b-glucan | Tissue type:tumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 04_UK49 | Treatment:13C6Glc_100ug/ml b-glucan | Tissue type:tumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 31_UK49 | Treatment:13C6Glc | Tissue type:nontumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 32_UK49 | Treatment:13C6Glc | Tissue type:nontumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 01_UK49 | Treatment:13C6Glc | Tissue type:tumor | normalized corrected peak area |
Retsch homogenization (IC-FTMS2) | 02_UK49 | Treatment:13C6Glc | Tissue type:tumor | normalized corrected peak area |